Sanofi (SNY) reported fiscal Q3 business net income Friday of 3.55 euros ($3.97) per share, up from 2.91 euros a year earlier.
Analysts polled by FactSet expected 2.74 euros.
Revenue for the quarter ended Sept. 30 was 14.44 billion euros, up from 12.43 billion euros a year earlier.
Analysts expected 13.60 billion euros.
The drugmaker upgraded its 2026 outlook and now expects business EPS and sales to grow by mid-teens and low-teens percentages, respectively.
Analysts surveyed by FactSet expect EPS of 8.53 euros on revenue of 49.73 billion euros.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments